Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival

Cancer

Volumn 117, Issue 10, 2011, Pages 2186-2191

  Wilgus, May Lin ^a   Borczuk, Alain C ^a   Stoopler, Mark ^a   Ginsburg, Mark ^a   Gorenstein, Lyall ^a   Sonett, Joshua R ^a   Powell, Charles A ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

invasion; lung adenocarcinoma; lysyl oxidase; stroma; transforming growth factor

Indexed keywords

BIOLOGICAL MARKER; PROTEIN LYSINE 6 OXIDASE;

AGED; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTEIN-LYSINE 6-OXIDASE; TUMOR MARKERS, BIOLOGICAL;

EID: 79955496481     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25768     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Alberg AJ, Ford JG, Samet JM,; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical guidelines (2nd edition). Chest. 2007; 132 (3 suppl): 29S-55S. (Pubitemid 47502798)
3. Spira A, Ettinger DS., Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350: 379-392. (Pubitemid 38101633)
4. Al-Kattan K, Sepsas E, Fountain SW, Townsend ER., Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997; 12: 380-384. (Pubitemid 27397975)
5. World Health Organization. International Histological Classification of Tumours. 2nd ed. Berlin: Springer- Verlag; 1988.
6. Borczuk AC, Fang Q, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol. 2009; 33: 462-469.
7. Sakurai H, Maeshima A, Watanabe SI, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004; 28: 198-206. (Pubitemid 38124728)
8. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA., Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med. 2005; 172: 729-737. (Pubitemid 41324228)
9. Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant cancers. Cancer Res. 1998; 58: 3101-3104. (Pubitemid 28335093)
10. Biswas S, Chytil A, Washington K, et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res. 2004; 64: 4687-4692. (Pubitemid 38924506)
11. Borczuk AC, Papanikolaou N, Toonkel RL, et al. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene. 2008; 27: 557-564.
12. Lucero HA, Kagan HM., Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci. 2006; 63: 2304-2316. (Pubitemid 44653041)
13. Maki J., Lysyl oxidases and mammalian development and certain pathologic conditions. Histol Histopathol. 2009; 24: 651-660.
14. Payne SL, Hendrix MJC, Kirschmann DA., Paradoxical roles for lysyl oxidase in cancer-a prospect. J Cell Biochem. 2007; 101: 1338-1354. (Pubitemid 47242767)
15. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007; 2: 706-714. (Pubitemid 47357522)
16. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC., Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res. 1998; 58: 1285-1290. (Pubitemid 28183220)
17. Jansen MK, Csiszar K., Intracellular localization of the matrix enzyme lysyl oxidase in polarized epithelial cells. Matrix Biol. 2007; 26: 136-139. (Pubitemid 46187037)
18. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM., Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci USA. 1997; 94: 12817-12822. (Pubitemid 27518434)
19. Tlsty TD, Coussens LM., Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006; 1: 119-150.
20. Finak G, Berlos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14: 518-527. (Pubitemid 351655218)
21. Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA. 2010; 107: 2177-2182.
22. Gold LI., The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog. 1999; 10: 303-360. (Pubitemid 30058460)
23. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440: 1222-1226.
24. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009; 15: 35-44.
25. Bondareva A, Downey CM, Ayres F, et al. The lysyl oxidase inhibitor, beta-aminoproprionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS One. 2009; 4: e5620.
26. Granchi C, Funaioli T, Erler JT, Giaccia AJ, Macchia M, Minutolo F., Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours. ChemMedChem. 2009; 4: 1590-1594.